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Abstract
Purpose Controlled trials have shown that total disc re-
placement (TDR) can provide pain and disability relief to
patients with degenerative disc disease; however, whether
these outcomes can also be achieved for patients treated in
normal surgical practice has not been well documented.
Methods This prospective, international study observed
changes in disability and back pain in 134 patients who
were implanted with Maverick TDR within the framework
of routine clinical practice and followed for 2 years post-
surgery. Primary and secondary outcomes were the dif-
ferences from baseline to 6 months post-surgery in the
means of the Oswestry Disability Index and the change in
back pain intensity assessed on a 10-cm visual analogue
scale, respectively. Mean patient age at surgery was
43 years, but ranged up to 65 years.
Results One hundred twenty-three patients had an im-
plant at one level, 10 patients at two levels, and one patient
at three levels. Statistically significant improvements in
mean disability (-25.4) and low back pain intensity (-4.0)
scores were observed at 6 months postoperatively
(P\ 0.0001 for both) in the hands of experienced surgeons
([10 TDRs per centre). During the study, 56 patients
(42 %) experienced a complication or adverse event.
Conclusions This is the first international observational
study to report outcomes of TDR in real-world clinical
settings. We showed statistically significant improvements
in disability and pain scores at 6 months following Mav-
erick TDR, which were maintained for 2 years alongside
an acceptable rate of perioperative complications. The
safety and tolerability shown in this observational study
were comparable to those from controlled trials.
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Introduction
Since 50 years, a pathologic disc associated with lumbar
degenerative disc disease (DDD) that did not respond to
conservative care has been preferentially treated by spinal
fusion. As an alternative, in 1984, lumbar spinal arthro-
plasty or disc replacement emerged [1–4]. Disc replace-
ment can provide pain relief by resecting the diseased
intervertebral disc and dynamically stabilising the segment,
allowing restoration and maintenance of spine biome-
chanics. Compared to fusion, this is expected to reduce the
incidence of adjacent segment degeneration [5–7].
The Maverick disc, a two-piece lumbar disc prosthesis,
can be implanted at any spinal level from T12/L1 to L5/S1.
It has a semi-constrained metal-on-metal design, preserv-
ing motion by a ball-and-socket construct with a physio-
logical posterior centre of rotation [8]. A 2-year
randomised controlled trial (RCT) demonstrated statistical
superiority of Maverick over spinal fusion based on key
clinical outcomes, including disability and pain [9].
The optimal patient population for total disc replace-
ment (TDR) is not fully defined [9–11]. Available infor-
mation outside a controlled clinical study setting comes
from a single national registry [10, 12]. The objective of
this first international observational study was to investi-
gate changes in disability and back pain in a broad patient
population treated with Maverick TDR in varied surgical
practices reflecting different national standards of care.
Patients and methods
Study design and participants
This prospective observational study of normal surgical
practice for the MAV Motion Segment Replacement
(MSR; A-MAV and O-MAV; Medtronic Sofamor Danek,
Memphis, TN, USA) was conducted at 11 centres in France
(7: Clinique de Neurochirurgie Hoˆpital Roger Salengro,
Centre Hospitalier Universitair Pellegrin Tripode; Centre
Hospitalier de Meulan, Service de Neurochirurgie Hoˆp
Nice, AP-HP Hoˆpital Beaujon, Clinique du Cours Dillon,
Centre Hospitalier La Timone), Germany (3: Univer-
sita¨tklinikum Magdeburg, Praxis fu¨r Orthopa¨die und Neu-
rochirurgie Potsdam, Charite´ Berlin–Klinik fu¨r
Orthopa¨die), and Canada (1: Montreal General Hospital)
from February 2009 to July 2013. One hundred thirty-four
patients with back pain were implanted with Maverick
discs and followed for 2 years. Study centres were required
to have at least 10 TDR per year prior to participation. The
study is registered at http://www.clinicaltrials.gov
(NCT01338493).
Patients eligible for MAV MSR disc replacement ac-
cording to the labelling were included at the discretion of
the surgeon and managed in routine clinical practice. Pa-
tients were not excluded for having fusion-treated degen-
erative spondylolisthesis adjacent to the implantation level.
Patients were enroled by signing informed consent and
having their data entered in the electronic case report form
(eCRF).
Ethical considerations
This study was conducted in agreement with the Declara-
tion of Helsinki and local regulations of the participating
countries. According to the requirements, a notification
letter regarding the registry was sent to, or written approval
was obtained from, the Ethics Committee (EC)/Institu-
tional Review Board (IRB)/Human Research Ethics Com-
mittee (HREC) before the start of the study. Data were
collected by web-based eCRF according to the legislation
for each participating country. All enrolled patients gave
written informed consent in their local language before
participation.
Study procedures
Patients were treated by lumbar spinal arthroplasty. A
complete anterior discectomy was performed followed by
A-MAV (implant for anterior insertion at levels T12–S1,
126 implants) or O-MAV (implant for oblique insertion at
levels L4–L5, 20 implants) insertion to replace the dam-
aged lumbar intervertebral disc [8] at up to three levels;
patients could also be treated with adjacent fusion. All
procedures and assessments (Table 1) were part of the
standard treatment a patient outside of the study would also
receive.
Outcome measures
Primary outcome was change from baseline at 6 months
post-surgery of mean Oswestry Disability Index (ODI
version 2.1). Secondary outcome was change at 6 months
versus baseline in back pain intensity assessed on a 10-cm
visual analogue scale [VAS; 0 cm (no pain) to 10 cm
(worst possible pain)]. The percentage of patients attaining
a C15-point improvement in ODI—criterion for success
defined by the US Food and Drug Administration (FDA)
[9]—was calculated.
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Tertiary outcomes included changes from baseline at 12
and 24 months post-surgery in ODI, leg pain intensity
(VAS), back and leg pain frequency [VAS; 0 cm (pain
none of the time] to 10 cm (pain all of the time)], and 6 and
24 month patient quality of life improvement from baseline
[the Physical Component Summary (PCS) and Mental
Component Summary (MCS) of the Short-Form Health
Survey (SF-36) v2]. The percentage of patients attaining a
minimal clinically important difference of a C4.9-point
increase in PCS [13] was calculated. Baseline and post-
operative (6, 12, and 24 months) measures of range of
motion at the operated level(s), work status, pain medica-
tion, and non-drug pain treatment were also compared.
Patient treatment satisfaction and adverse events (AEs)
were documented up to 24 months after surgery.
All adverse findings and complications were reported
regardless of severity, causation, or relatedness to the im-
plant or surgical procedure. Relationship of AEs to surgery
or device was not categorised by the investigators.
Statistical analysis
Statistical analysis was carried out for all patients im-
planted with a Maverick disc using the Statistical Analysis
System (SAS) software package version 9.2 (SAS Institute
Inc, Cary, NC, USA).
Continuous variables are described as means, standard
deviations (SDs), and the 95 % confidence interval (CI) of
the mean. For comparisons from baseline to post-surgery, a
two-sided t test was applied. The normality assumption was
tested by a Shapiro–Wilk test to report a two-sided
Wilcoxon signed-rank test if the normality assumption was
violated. However, for all instances where the Shapiro–
Wilk test indicated a significant deviation from normality,
both the t test and the Wilcoxon signed-rank test were
significant with P\ 0.0001 for all comparisons reported.
Statistical significance was defined as P B 0.05. As sec-
ondary analysis, the differences in mean ODI score from
baseline to 6, 12, and 24 months postoperatively was
analysed with a repeated measurements analysis of vari-
ance (ANOVA) model. Changes in mean VAS score for
back pain intensity were analysed over time in a similar
manner. Both the absolute and relative frequencies of
categorical variables were calculated.
Mean SF-36 PCS and MCS scores were calculated only
for patients who completed C50 % of the items. For pa-
tients who completed C50 % of the items but who had
missing values, the average score across the completed
items was calculated to estimate the missing item values.
Other outcomes with missing values were calculated
without inclusion of a value for the patient in question.
Results
One hundred thirty-four patients with back pain were im-
planted with Maverick discs and followed for 2 years with
104 (78 %) evaluable patients remaining at 24 months
(Fig. 1). The vast majority of patients complied with in- and
exclusion criteria for Maverick disc replacement (Table 2).
Because of the observational study design, intended to re-
flect routine practice, patients with extended indications
Table 1 Summary of procedures and assessments

















Pain medications and non-drug pain
treatments
x x x x x
Neurological examination x x x x x
Patient questionnaires x x x x
Working/activity status x x x x
Neutral X-ray x x x x x
Flexion/extension X-rays x x x x
MRI x
Surgical data x
Patient satisfaction x x x
Adverse events x x x x x
MRI magnetic resonance imaging
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were included in the analysis. The number of implants per
patient, length of surgery, and blood loss observed during
the study are described in Table 3. The lumbar spine was
approached anteriorly through retroperitoneal exposure for
most patients [n = 131; 98.5 %; transperitoneal: n = 2;
1.5 % (approach data are missing for one patient)].
Disability
Mean (SD) ODI score was 50.1 (16.2) at baseline and 24.2
(18.5) at 6 months. Mean ODI score had reduced sig-
nificantly by 25.4 points (patient with paired values:
n = 122; 95 % CI -29.0 to -21.9; P\ 0.0001; Fig. 2)
and it continued to decrease through 24 months. According
to FDA success criterion (C15-point improvement in ODI)
[9], 74.6 and 75.2 % of patients had successful outcomes at
6 and 24 months, respectively.
Pain and pain medication
Mean low back pain intensity scores (VAS) decreased
significantly from baseline to 6 months (-4.0; 95 % CI
-4.5 to -3.4; P\ 0.0001), and further reductions were
noted through 24 months (Fig. 3). Reductions in the in-
tensity and frequency of leg pain over the same time period
were also noted (Table 4).
The number of patients requiring non-drug pain inter-
ventions or pain medicine post-surgery was reduced
(Table 4), as was the usage of all types of medications:
nonopioids or nonsteroidal anti-inflammatory drugs, mild
and strong opioids, neuropathic pain medications, and
adjuvants.
Enrolled (n = 139)
Not implanted (n = 5)
•  Withdrew consent (n = 1)
•  Premature discontinuation (n = 4)
Missed visit (n = 1) 
Missed visit (n = 8) 
Death: ischemic stroke (n = 1)
Lost to follow-up (n = 11)
Withdrawal (n = 1)
Lost to follow-up (n = 17)
Implanted with Maverick™ disc 
(n = 134)
Discharged (n = 134)
100% of implanted patients
6-Month assessment (n = 132)
99% of implanted patients
12-Month assessment (n = 113)
84% of implanted patients
24-Month assessment (n = 104)




Fig. 1 Patient enrolment and follow-up. This study enrolled 139
patients. The number of patients with evaluable data from Maverick
disc implantation (n = 134) through follow-up at 24 months
(n = 104) is described. The bold boxes on the left describe the
patients who had no evaluable data for the subsequent evaluations,
whereas the boxes on the right describe those patients who missed
visits, but completed subsequent assessments




Male, n (%) 64 (48 %)
Age (years) at surgery, mean years (SD; range) 43 (9; 22–65)
BMI (kg/m2), mean (SD) 24.8 (3.3)
Months since onset of discogenic pain, median
(Q1–Q3)
15 (7–33)
Period of conservative treatment before Maverick implant, n (%)
0–3 months 9 (7 %)
3–6 months 19 (14 %)
6–12 months 27 (20 %)
1–2 years 28 (21 %)
[2 years 51 (38 %)
Previous lumbar surgeries, n (%)
At implanted level, n (%) 41 (31 %)
Indications for total disc replacement 26 (19 %)
Degenerative disc disease 100 %
Leg pain (VAS C 2) 88 %
SD standard deviation, VAS visual analogue scale
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Range of motion
Postoperatively, most patients with available radiographs
had C3 of motion (extension–flexion) at the implant level:
84 % (53/63), 87 % (52/60), and 85 % (52/61) at 6, 12, and
24 months, respectively. By 6, 12, and 24 months, mean
(SD) range of motion increased to 8.4˚ (4.4; 95 % CI
7.3–9.5), 8.4 (4.9; 95 % CI 7.1–9.7), and 9.4 (5.6; 95 %
CI 8.0–10.9), respectively, from the mean pre-operative
range of motion of 6.2 (4.8; 95 % CI 5.0–7.5).
Work status
At baseline, 58 patients (43 %) were not working, 55 of
them (95 %) ascribing this to back problems. Six months
post-surgery, this number increased to 75 (57 %) but only
49 patients (65 %) ascribed this to back problems. By 12
and 24 months, these numbers had reduced below baseline
to 39 (37 %) and 36 (36 %), respectively, with 20 patients
citing back problems. Figure 4 shows return to work in-
formation of professional workers who had to stop working
due to back problems pre-surgery.
Quality of life
Mean SF-36 PCS and MCS scores significantly increased
postoperatively, with an 11.6-point and 8.8-point increase
from baseline at 6 months, then to 14.4 and 9.8 at
24 months (P\ 0.0001 for all; Fig. 5). 76 % of patients
had a successful (C4.9-point increase in PCS) outcome at
24 months.
Table 3 Surgical parameters
Number of implants Total patients
(n = 134)
Operative time
(min), mean (SD), n
Blood loss (mL),
mean (SD), n




One implant, no fusion 101 (43), 77 150 (121), 70
One implant, adjacent fusion 149 (42), 40 273 (163), 35
Two levels, n (%) 10 (7%) 90 (43) 270 (71)
L3–L4 ? L4–L5 2 (2%)
L3–L4 ? L5–S1 1 (1%)
L4–L5 ? L5–S1 7 (5%)


















Pre-operation 6 Months 12 Months 24 Months
(n = 132) (n = 122) (n = 106) (n = 103)
Fig. 2 Reduction in disability. Disability was measured pre-op-
eratively and at 6, 12, and 24 months postoperatively using the
Oswestry Disability Index (ODI version 2.1). Compared with pre-
operative mean ODI scores, all follow-up mean ODI scores were


























(n = 126) (n = 120) (n = 112) (n = 110) (n = 104) (n = 100) (n = 104) (n = 101)
6 Months 12 Months 24 Months
P < 0.0001, difference from
pre-operation to follow-up
Fig. 3 Low back pain relief. Low back pain (LBP) intensity and
frequency were assessed pre-operatively and at 6, 12, and 24 months
postoperatively using the 10-cm visual analogue scale [VAS; 0 cm
(no pain) to 10 cm (worst possible pain)]. Compared with pre-
operative mean VAS scores, all follow-up mean VAS scores were
statistically significant (error bars depict the 95 % confidence
intervals)
Eur Spine J (2015) 24:2047–2055 2051
123
Patient satisfaction
Patients were asked (1) whether they would have the
treatment again, and (2) whether they had completely
Table 4 Changes in tertiary outcomes from pre-operation (baseline) to 2 years







Intensity, mean (SD), total n 5.2 (3.0), 125 2.3 (2.4), 113 2.4 (2.9), 103 2.8 (2.8), 104
Frequency, mean (SD), total n 5.7 (3.1), 119 2.7 (2.9), 111 2.7 (3.2), 100 2.8 (3.1), 101
Patients taking pain medicationb, n/total (%) 115/133 (87 %) 79/127 (62 %) 44/104 (42 %) 43/96 (45 %)
Patients using non-drug pain treatmentsb, n/total (%) 90/134 (67 %) 68/127 (54 %) 41/104 (39 %) 32/95 (34 %)
Patient satisfaction
Would the patient have the treatment again?c
Yes, n/total (%) 101/120 (84 %) 76/96 (79 %) 77/94 (82 %)
No, n/total (%) 5/120 (4 %) 7/96 (7 %) 8/94 (9 %)
Unsure, n/total (%) 14/120 (12 %) 13/96 (14 %) 9/94 (10 %)
Have you completely recovered?d
Improved, n/total (%) 117/122 (96 %) 89/99 (90 %) 80/99 (81 %)
Worsened, n/total (%) 1/122 (1 %) 1/99 (1 %) 9/99 (9 %)
No change, n/total (%) 4/122 (3 %) 9/99 (9 %) 10/99 (10 %)
SD standard deviation, VAS visual analogue score
a Improvements from pre-operative in each group were examined by paired t test and shown to be highly significant (P\ 0.0001)
b Not specific to lumbar pain; non-drug pain interventions included structured physical therapy, bracing or orthoses, spinal injections or nerve
blocks, and back school
c ‘‘Yes’’ describes those who answered either ‘‘definitely true’’ or ‘‘mostly true,’’ while ‘‘no’’ describes those who answered ‘‘definitely false’’
and ‘‘mostly false’’
d ‘‘Improved’’ describes those who answered, ‘‘completely recovered,’’ ‘‘much improved,’’ and ‘‘slightly improved,’’ while ‘‘worsened’’ de-
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Fig. 4 Return to work. Patients’ work status was assessed postop-
eratively through 24 months. Only professional workers who had to
stop working before surgery are depicted below (not those who were
retired, unemployed, a student, or a homemaker). The number of
professional workers who returned to work post-surgery was divided
by the total number of professional workers for which data on


















44.6 45.0 45.0 45.5
46.0
Pre-operation
(n = 127) (n = 104) (n = 99) (n = 100)
6 Months 12 Months 24 Months
P < 0.0001, difference from
pre-operation to follow-up
Fig. 5 Improvement in quality of life. Patient quality of life was
measured pre-operatively and at 6, 12, and 24 months postoperatively
using the Physical Component Summary (PCS) and Mental Compo-
nent Summary (MCS) of the Short-Form Health Survey (SF-36) v2.
Compared with pre-operative mean scores, all follow-up mean PCS
and MCS scores were statistically significant (error bars depict the
95 % confidence intervals)
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recovered pre-operative health: they reported an overall
positive perceived effect (Table 4).
Results of other tertiary outcomes are shown in Online
Resource 1.
Adverse events
Fifty seven patients (42 %) experienced a complication or
AE. AEs occurring within 6 months post-surgery are de-
scribed in Table 5. Between 6 and 24 months, the fol-
lowing additional AEs occurred (in parentheses the number
of events not resolved at study end): 13 late radiculopathies
(10), 6 occurrences of late nonspecific low back pain (3),
and 18 other events (10). One foreign body (allergic) re-
action was observed during the 2-year follow-up period.
Resolution of AEs included re-operation for abdominal
wall weakness or haematoma for three patients and re-
moval of the implant for the patient with the foreign body
reaction for persisting pain. Two other surgeries—one on
the foot, one on the hip—were not linked to the spine
pathology.
Discussion
This prospective observational study examined the effec-
tiveness of the Maverick TDR prosthesis under real-life
surgical conditions in patients receiving routine standard
care for DDD at their respective centres. It is the first in-
ternational study reporting outcomes of TDR in a wide
patient population treated under different national stan-
dards of care. To date, limited information derived from a
national registry (Switzerland) is available on outcomes
following TDR in patients treated outside a controlled
clinical study setting [10, 12]. Two publications of TDR
based on a national registry have reported reductions in low
back pain at a mean follow-up time of 8 months [10] and
1 year [12]. Changes in disability, however, were not
measured in these observational study settings.
Despite the uncontrolled nature of current study, the
findings are similar to those of previous prospective ran-
domised studies [2, 9, 14]. This registry demonstrated
statistically significant improvements in its primary and
secondary endpoints—disability (ODI) and back pain
(VAS) scores 6 months postoperatively—which were
maintained through 12- and 24-month follow-ups. Change
in ODI met the criteria for a clinically important difference
as defined by the FDA with 75.2 % of patients having C15-
point improvement at 24 months [8]. In the randomised
controlled trial (RCT) comparing Maverick disc implants
versus interbody fusion, this was 82.2 % of the patients [9].
Mean low back pain scores observed in both studies un-
derwent significant reductions from pre-operation to 6 and
24 months (registry: P\ 0.0001; RCT: P\ 0.001),
although a direct comparison of the results is not possible
because the RCT employed a 0–100 VAS scale and this
study used a 0–10 scale [9]. Like the prospective ran-
domised studies, reductions in pain and disability were
attained in the first year of this study, and lower values
maintained in the second year [2, 9, 14]. Changes from pre-
operation to 6 and 24 months in mean ODI and VAS scores
observed in this study are also comparable to other
prospective studies of Maverick TDR, including the 4-year
prospective study [4, 9]. Taken together, these findings
Table 5 Early adverse events (up to 6 months post-surgery)
Adverse event category Early adverse events








Abdominal wall 9 4 5
Neuro-hypogastric plexus injury –
Neuro-access-related 13 5 8
Vascular 3 3
Visceral–bowel or peritoneum 1 1




Foreign body reaction –
Early nonspecific low back pain 5 1 2 2
Other 9 6 2 1b
a Specified by the investigator as completely asymptomatic radiological finding
b Death from ischaemic stroke
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suggest that Maverick TDR performed in current, real-life
surgical settings can provide similar outcomes to those
seen in trials.
The registry population had 64 % of patients that re-
turned to work 2 years postoperatively. In the Maverick
RCT, the multi-device RCT and the PRODisc prospective
nonrandomised study, the percentages should be 68 %,
74 % and 76 %, respectively [3, 9, 14]. Only 20 % of this
registry population ascribed their lack of work to back
problems. The work status at 2 years in this registry was
equivalent to that observed in the prospective, randomised
investigational device exemption (IDE) CHARITE trial:
63 % [2]. Comparisons of work status across studies con-
ducted at different times and in different locations, how-
ever, must be tempered by the influence of the current
employment rate and local practice recommendation for
post-surgical work hiatus, and type of study.
Like the Maverick RCT and the Maverick 4-year
prospective study, this registry noted a significant increase
in the patient’s quality of life from pre-surgery to 6 months
and 2 years post-surgery [4, 9]. A total of 78 % of patients
in the Maverick RCT reported that they had either com-
pletely recovered or were much improved after 2 years [9]
compared with 81 % of reported improvements in this
registry. Furthermore, 82 % of patients in this registry
compared to 86 % of patients in the PRODisc study [3] and
73 % in the randomised IDE CHARITE trial reported that
they would have the treatment again [2].
The incidence of AEs (42 %)—prompting reporting—
during the 2-year follow-up in this observational study is
lower than the rate observed in the Maverick RCT ([80 %)
[9]. Overall complication rates reported in the published
literature range from 1 to 40 % [3]. One case of allergic
reaction was noted (first symptoms at 1 year) and the
prosthesis was explanted. The Maverick RCT also reported
one case of metallurgic allergy at 7 months [9]. This rare
problem has been previously noted and is due to the cre-
ation of ionic species at the metallic articulating surfaces
precipitating a cell-mediated hypersensitivity reaction
(type IV) [15, 16].
Limitations of this study are related to the nature of
multicentre observational non-comparative studies. These
include variations in surgical centre standards of care,
assessment, follow-up, and lack of a control group. At the
same time, this ‘‘real-life’’ setting offers insight into the
effectiveness of TDR for treating DDD with high external
validity.
In conclusion, this international prospective observa-
tional study shows that TDR performed by experienced
surgeons, leads to a statistically significant improvement in
disability (ODI) and pain (VAS) scores at 6 months, which
were maintained for 2 years, providing the first evidence of
the effectiveness of TDR in real-world clinical settings
across countries and patient populations, with an accept-
able rate of perioperative complications. The similarity in
outcomes of this registry compared to those from RCTs
support the use of registry data for assessing interventions.
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